Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Taylor Wimpey's H1 profits drop 21% as costs rise, pricing falls

(Sharecast News) - UK housebuilder Taylor Wimpey saw profits fall by more than a fifth in the first half as residual build cost inflation and weaker pricing hit margins, but said it now expects full-year completions to be at the top end of guidance after a solid operational performance. Adjusted pre-tax profit slumped 21% year-on-year to £187.7m, with the operating profit margin falling 2.4 percentage points to 12.0%.

Revenues were 7% lower at £1.52bn as the company completed 4,728 homes, down from 5,120 in the first half last year, while the average selling price slipped 0.9% to. £317,000.

Taylor Wimpey ended the half with an order book of 7,451 homes at a value of £2.01bn, compared with 7,866 and £2.15bn the year before, respectively.

"Looking to the second half, our performance to date means we now expect to deliver 2024 full year UK completions towards the upper end of our previous guidance range of 9,500 to 10,000," said chief executive Jennie Daly.

The negative impact of residual build cost inflation and weaker pricing should reduce in the second half, while the recovery of fixed costs will improve as volumes increase, meaning that underlying margins should pick up.

As such, Daly also said the company still expects to hit market expectations for operating profit over the full year, which currently stand at £416m, down from £470.2m in 2023.

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.